Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study
Frontiers in Oncology · 27.01.2026 · 16
DOI: 10.3389/fonc.2026.1737930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 27.01.2026. Verfasst von Nikša Librenjak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Centre Zagreb, Zagreb, Grad Zagreb, Croatia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metastatic colorectal cancer (mCRC) is a major cause of cancer-related mortality, with limited curative options despite advances in targeted therapies. Reliable prognostic biomarkers are needed to guide treatment. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) may predict poor outcomes. This study evaluated the prognostic value of serial NLR and SII assessments in first-line mCRC therapy.
Methods
In this single-center, retrospective, observational study, we obtained data on 258 patients who started first-line systemic chemotherapy from the beginning of 2016 until the end of 2018. Baseline (pretreatment) and 3-month post-treatment values of NLR and SII were used to determine their prognostic value for treatment outcomes, which were measured as progression-free survival (PFS) and overall survival (OS).
Results
Patients were divided by pretreatment median NLR (3.19) and SII (810). Low NLR was associated with longer PFS (15.4 vs. 9.5 months, p=0.031) and OS (39.1 vs. 27.2 months, p=0.002). After 3 months, PFS difference increased (14.3 vs. 4.5 months, p<0.001); OS was longer but not significantly (35.3 vs. 20.1 months, p=0.14). Low SII after three months of therapy was linked to improved PFS (14.1 vs. 6.8 months, p<0.001) and OS (36.4 vs. 21.6 months, p=0.001), while at baseline assessment it was associated with longer OS (39.4 vs. 27.1 months, p=0.003), but not with PFS (13.9 vs. 10.6 months, p=0.11). Multivariate analysis showed pretreatment NLR and SII were independent prognostic factors for OS, but not PFS. Post-treatment NLR was prognostic for PFS only, while post-treatment SII was prognostic for both OS and PFS.
Conclusions
Serial evaluation of NLR and SII could identify patients who are at increased risk of poor survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, University Hospital Centre Zagreb, Zagreb, Grad Zagreb, Croatia.
- School of Dental Medicine, University of Zagreb, Zagreb, Grad Zagreb, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Grad Zagreb, Croatia.
Zitieren
APA
Librenjak, N., Adžić, G., Kekez, D., Goršić, I., Prejac, J., & Pleština, S. (2026). Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1737930
Vancouver
Librenjak N, Adžić G, Kekez D, Goršić I, Prejac J, Pleština S. Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1737930
BibTeX
@article{Librenjak2026,
author = {Librenjak, Nikša and Adžić, Gordan and Kekez, Domina and Goršić, Irma and Prejac, Juraj and Pleština, Stjepko},
title = {Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1737930}
}
EUVIMED